Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily reading drill restore lost reading skills in glaucoma?

NCT ID NCT07741812

Symptom relief Sponsor: Universiti Sains Malaysia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This trial tests whether a structured reading rehabilitation module can improve reading speed and reduce errors in people with glaucoma, a condition that often impairs vision. Participants will practice the module for 20-30 minutes daily, at least 3 days a week, for 6 months. The study will compare their reading performance and self-reported quality of life against a control group receiving standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Reading rehabilitation module
What this could lead to
If effective, this module could offer a simple, non-invasive way to help glaucoma patients read faster and with fewer errors, potentially improving their daily lives and independence.
What could go wrong
This is a relatively small trial, and the benefits may vary. Reading improvement might not translate to overall quality of life, and the module requires consistent daily practice, which may be challenging for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18- 80 years old. * Confirmed diagnosis of bilateral Primary Open Angle Glaucoma (POAG),Primary Angle Closure Glaucoma (PACG), Normotensive Glaucoma (NTG) and Juvenile Open Angle Glaucoma (JOAG). * Bilateral visual acuity of 6/60 and better. * Bilateral visual field defect more than 10degree from fixation. * Phakic without visually significant cataract. * Pseudophakic for more than 3 months prior to recruitment. * Literate patients. Exclusion Criteria: * Ocular diseases other than glaucoma (e.g., age-related macula degeneration, diabetic retinopathy, moderate to severe cataract). * Other comorbidities that affect memory (e.g., stroke, cognitive disorders). * Cognitive disorders (e.g., diagnosed dementia or cognitive impairment). * Poorly controlled diabetes mellitus, hypertension and hyperlipidaemia. * Other media opacities. * History of previous intraocular surgery other than uncomplicated cataract within past 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile open angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

angle-closure glaucoma glaucoma juvenile open angle glaucoma low tension glaucoma open-angle glaucoma primary angle-closure glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile open angle glaucoma Normotensive glaucoma Primary angle-closure glaucoma Primary open angle glaucoma (POAG)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universiti Sains Malaysia

    Kota Bharu, Kelantan, 16150, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.